NCT03902509

A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

A Randomized, Controlled, Multi-site Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Beijing Continent Pharmaceutical Co, Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Using Pirfenidone to treat Grade 2 or Grade3 radiation-induced lung injury, and observe the efficacy and safety of the drug.

Detailed description

The study is a randomized, controlled, multi-site clinical trial.

Conditions

• Radiation-induced Lung Injury

Interventions

Type	Name	Description
DRUG	Pirfenidone	pirfenidone capsule made in China
DRUG	basic treatment	glucocorticoid and expectant treatment etc.

Timeline

• Start date: 2019-05-24
• Primary completion: 2023-12-04
• Completion: 2023-12-04
• First posted: 2019-04-04
• Last updated: 2025-05-04

Locations

2 sites across 1 country: China